Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP-307 in Moderate-to-Severe Crohn's Disease
CTR20180433Phase 2Terminated
- Sponsor
- Concord Biotech
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of icanbelimod in Crohn's disease, sponsored by Concord Biotech. Started Aug 2018; status: terminated.
02
Drugs
icanbelimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20180433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180433.